Awardee: Stephen Rowe
Institution: University of Alabama at Birmingham
Award Amount: $51,500
Funding Period: January 1, 2016 - December 31, 2016
An open label N of 1 study to evaluate the safety and efficacy of long-term treatment with Ivacaftor in combination with ATALUREN (PTC124) in Subjects with Nonsense Mutation Cystic Fibrosis
Previous
Previous
Systematic Evaluation of a Cluster of Nonsense Mutations in Exon 22 of CFTR to Inform Treatment (Copy)
Next
Next